Research Report for: Valeant Pharmaceuticals International, Incorporated (NYSE:VRX)

touch screen graph on tablet

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported the earnings of $1.55/Share in the last quarter where the estimated EPS by analysts was $1.75/share. The difference between the expected and actual EPS was $-0.2/share, which represents an Earnings surprise of -11.4%.

Many analysts are providing their Estimated Earnings analysis for Valeant Pharmaceuticals International, Inc. and for the current quarter 18 analysts have projected that the stock could give an Average Earnings estimate of $1.22/share. These analysts have also projected a Low Estimate of $1.04/share and a High Estimate of $1.53/share.

In case of Revenue Estimates, 14 analysts have provided their consensus Average Revenue Estimates for Valeant Pharmaceuticals International, Inc. as 2.34 Billion. According to these analysts, the Low Revenue Estimate for Valeant Pharmaceuticals International, Inc. is 2.28 Billion and the High Revenue Estimate is 2.5 Billion. The company had Year Ago Sales of 2.79 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for VRX to be -51.2%. They are projecting Next Quarter growth of -13.4%. For the next 5 years, Valeant Pharmaceuticals International, Inc. is expecting Growth of 11.07% per annum, whereas in the past 5 years the growth was 19.56% per annum.

Some buy side analysts are also providing their Analysis on Valeant Pharmaceuticals International, Inc., where 3 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 13 said it’s a HOLD, 4 reported it as Underperform and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 19 Analysts reported that the Price Target for Valeant Pharmaceuticals International, Inc. might touch $55 high while the Average Price Target and Low price Target is $23.97 and $9 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Valeant Pharmaceuticals International, Inc. got Downgrade on 15-Dec-16 where investment firm Morgan Stanley Downgrade the stock from Overweight to Equal-Weight.

Valeant Pharmaceuticals International, Inc. closed its last trading session at $15.35 with the gain of 6.84%. The Market Capitalization of the company stands at 5.78 Billion. The Company has 52-week high of $101.4 and 52-week low of $13. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 11.99% where SMA50 and SMA200 are -0.49% and -31.84% respectively. The Company Touched its 52-Week High on Feb 2, 2016 and 52-Week Low on Dec 15, 2016.

The Relative Volume of the company is 2.31 and Average Volume (3 months) is 18.33 million. Valeant Pharmaceuticals International, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 3.13.

The company shows its Return on Assets (ROA) value of -4.7%. The Return on Equity (ROE) value stands at -42.9%. While it’s Return on Investment (ROI) value is 3.7%.

While looking at the Stock’s Performance, Valeant Pharmaceuticals International, Inc. currently shows a Weekly Performance of 7.61%, where Monthly Performance is 6.22%, Quarterly performance is -30.48%, 6 Months performance is -29.37% and yearly performance percentage is -80.81%. Year to Date performance value (YTD perf) value is 12.95%. The Stock currently has a Weekly Volatility of 5.40% and Monthly Volatility of 4.84%.